SL
Silence Therapeutics plc
SLN · NASDAQ
$10.64 -0.65% (-$0.07)
1M -22.28%
Market Cap $502.6M
P/E Ratio -
Div. Yield -
ROE 106.90%
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Weak
1/9Valuation
0 /100
Expensive P/S 818.13x
P/B 13.06x
P/E N/A
Growth
22 /100
Declining Rev. growth 68.36%
Book val. growth 41.33%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 51.00%
Net margin 9,755.61%
Op. margin 11,003.00%
Quality
0 /100
Poor ROIC 176.21%
ROE 106.90%
ROA 56.32%
Debt
33 /100
High Debt/Equity -0.00x
Current ratio 7.42x
Int. coverage N/A
Stability
41 /100
Moderate Beta 1.42x
Rev. volatility 90.95%
EPS volatility 11.98%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o SLN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Iain Gladstone Ross
Employees
88
Headquarters
London
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report